The new catheter leads to a significant reduction in pulmonary artery obstruction



A device known as Al-Bashir Researchers from the Lewis Katz School of Medicine at Temple University report that angioplasty catheters (THROMBOLEX, Inc.) significantly reduce the size of blood clots present in the pulmonary arteries, improving heart function in patients with pulmonary embolism. Innovation session at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference in Boston. The hack was described in detail in a report that was simultaneously published online at Journal of the American College of Cardiology: Cardiovascular Interventions.

Evidence of Bashir’s performance The catheters come from data collected in the RESCUE Trial sponsored by the National Institutes of Health (NIH), a clinical study designed to assess safety and effectiveness Catheterization as a new treatment for pulmonary embolism. The magnitude of the reduction in the size of pulmonary artery-occlusive clots in the RESCUE trial was significantly greater than the reductions reported for therapies currently used in the treatment of pulmonary embolism.

“For the first time, we can show that this treatment not only leads to a significant reduction in pulmonary artery obstruction in pulmonary embolism patients, but is also a very safe treatment,” said Riaz Bashir, FACC professor of medicine. Director of Vascular and Endovascular Medicine in the Department of Cardiology, Louis Katz College of Medicine and Temple University Hospital, Al-Bashir Inventor Vascular catheterization. Temple has partnered with THROMBOLEX™ Inc. She is also a co-inventor of Bashir Intravascular catheter platform technology, to promote device development, regulatory pathway, and marketing.

Bashir The catheter is made of an extendable basket with small infusion catheters. Once placed within the clot, the injection basket expands, creating new channels in the clot and thus increasing the surface area exposed for the clot-dissolving drugs delivered through the catheter. A larger area of ​​exposure accelerates clot breakdown and restores blood flow through the vessel.

The main clinical advantage of the Bashir ™ catheter is its ability to shorten the duration of treatment. “With existing devices, treatment by infusion of clot-dissolving drugs can be continued for up to 10 hours,” explained Vladimir Lachter, MD, assistant professor of medicine at the Louis Katz School of Medicine and an interventional cardiologist involved in the RESCUE trial. “With the BASHIR™ device, the infusion only lasts for five hours. Once the device is removed, we can see a significant reduction in pressure on the heart, providing significant relief to patients.”

As the PI of RESCUE, we are proud to be one of the top job site. One of the main reasons for this outstanding achievement is the multidisciplinary nature of the PERT program and the great benefit this technology can bring to the people we serve in Temple. “


Barth Raleigh, MD, associate professor of thoracic medicine and surgery, Lewis Katz School of Medicine, director of the Temple University Health System’s Pulmonary Obstructive Response Team (PERT), and investigator for the RESCUE trial

“The RESCUE trial was an extraordinary journey started by resentment of the historic outcomes of our patients with pulmonary emboli, fueled by the power of innovation, validated by the design and implementation of excellent clinical trials, and facilitated by a strong collaborative effort here in Temple and with Daniel Edmundovich,” said Daniel Edmundovich. “Our collaborators are nationwide.” In fact, the RESCUE trial represents an important treatment milestone for patients with obstructive pulmonary disease. “

Amy J. said: “It is also a testament to the scientific and clinical research of Dr. Bashir, Dr. Lachter, Dr. Raleigh, and their Temple teams. I am very proud to have these outstanding leaders as part of our Temple Health family.”

The Bashir™ catheter was approved by the US Food and Drug Administration (FDA) in 2019 to treat blood clots in the veins and arteries of the peripheral blood vessels. thrombolux It has now received FDA clearance for seven devices in the Bashir™ family of catheters, all of which are currently in marketing.

source:

Journal reference:

Bashir R. and others. (2022) A prospective, multicenter trial of drug-guided catheter-guided thrombolysis using intravascular Al-Bashir catheters for acute pulmonary embolism. Journal of the American College of Cardiology: Cardiovascular Interventions. doi.org/10.1016/j.jcin.2022.09.011.



Source link

Related Posts

Precaliga